항정신병약물로 유발된 고프로락틴혈증을 가진 조현병 환자의 삶의 질
Quality of Life of Antipsychotic-Induced Hyperprolactinemia in Patients with Schizophrenia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives：Antipsychotic-induced hyperprolactinemia causes physical symptoms, such as amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, and bone density loss, as well as psychiatric symptoms, such as depression and cognitive impairments. This study aimed to clarify the associations among hyperprolactinemia caused by antipsychotics in patients with schizophrenia, psychiatric pathology, and psychosocial factors. Methods：Ninety-nine patients with schizophrenia in the psychiatry department of a university hospital were registered between 2015 and 2017. All participants were assessed using structured questionnaires to elucidate psychopathology, social function, quality of life, and hyperprolactinemia-related side effects. The standard levels for hyperprolactinemia were 24ng/mL for women and 20ng/mL for men. Results：The average prolactin levels were 73.45±49.37ng/mL in patients with hyperprolactinemia and 9.16± 6.42ng/mL in those without hyperprolactinemia. The average prolactin level in women was significantly higher than that in men(p=0.04). Risperidone was most commonly administered in patients with hyperprolactinemia(58.1%, p<0.01), while aripiprazole was most commonly administered in those without hyperprolactinemia(44.7%, p<0.01). Patients with hyperprolactinemia had significantly higher Positive and Negative Syndrome Scale(p=0.03) and Patient Health Questionnaire-9(p=0.05) scores and had significantly lower Social and Occupational Functioning Assessment Scale(p=0.04) and Strauss–Carpenter Levels of Functioning Scale(p=0.03) scores than patients without hyperprolactinemia. There were no significant differences in side effects or quality of life between the two groups. Conclusion：These findings demonstrate that hyperprolactinemia confers negative effects on depression and social function, but does not directly affect the quality of life. These results suggest that patients with schizophrenia who take antipsychotics that increase prolactin or cause side effects of hyperprolactinemia need to be assessed and receive interventions for depression.
Abstract
Objectives：Antipsychotic-induced hyperprolactinemia causes physical symptoms, such as amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, and bone density loss, as well as psychiatric symptoms, such as depression and cognitive impairments. This study aimed to clarify the associations among hyperprolactinemia caused by antipsychotics in patients with schizophrenia, psychiatric pathology, and psychosocial factors. Methods：Ninety-nine patients with schizophrenia in the psychiatry department of a university hospital were registered between 2015 and 2017. All participants were assessed using structured questionnaires to elucidate psychopathology, social function, quality of life, and hyperprolactinemia-related side effects. The standard levels for hyperprolactinemia were 24ng/mL for women and 20ng/mL for men. Results：The average prolactin levels were 73.45±49.37ng/mL in patients with hyperprolactinemia and 9.16± 6.42ng/mL in those without hyperprolactinemia. The average prolactin level in women was significantly higher than that in men(p=0.04). Risperidone was most commonly administered in patients with hyperprolactinemia(58.1%, p<0.01), while aripiprazole was most commonly administered in those without hyperprolactinemia(44.7%, p<0.01). Patients with hyperprolactinemia had significantly higher Positive and Negative Syndrome Scale(p=0.03) and Patient Health Questionnaire-9(p=0.05) scores and had significantly lower Social and Occupational Functioning Assessment Scale(p=0.04) and Strauss–Carpenter Levels of Functioning Scale(p=0.03) scores than patients without hyperprolactinemia. There were no significant differences in side effects or quality of life between the two groups. Conclusion：These findings demonstrate that hyperprolactinemia confers negative effects on depression and social function, but does not directly affect the quality of life. These results suggest that patients with schizophrenia who take antipsychotics that increase prolactin or cause side effects of hyperprolactinemia need to be assessed and receive interventions for depression.
참고문헌 (45)
- Davies LM, "Economics and schizophrenia:the real cost", Br J Psychiatry, 165, pp.18~21 (1994)
- Awad AG, "Quality of life and new antipsychotics in schizophrenia are patients better off?", Int J Soc Psychiatry, 45, pp.268~275 (1999)
- Franz M, "Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients", Br J Psychiatry, 170, pp.422~425 (1997)
- Jones PB, "Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)", Arch Gen Psychiatry, 63, pp.1079~1087 (2006)
- Haddad PM, "Antipsychotic-induced hyperprolactinaemia", Drugs, 64, pp.2291~2314 (2004)
- Milano W, "Recent clinical aspects of hyperprolactinemia induced by antipsychotics", Rev Recent Clin Trials, 6, pp.52~64 (2011)
- 원승희, "만성 정신분열병 여성에서 고프로락틴혈증과 골밀도 및 골대사 표지의 상관", 생물치료정신의학, 12(2), pp.204~214 (2006), 대한생물치료정신의학회
- Kellner R, "Hyperprolactinemia, distress, and hostility", Am J Psychiatry, 141, pp.759~763 (1984)
- Koo JS, "Comparison and correlation of cognitive functions, prolactin, estrogen in women with schizophrenia on risperidone, olanzapine", Korean J Schizophr Res, 10, pp.53~61 (2007)
- 박영민, "항정신병 약물로 인한 고프로락틴혈증의 심각한 장·단기적 영향", 대한정신약물학회지, 20(4), pp.167~180 (2009), 대한정신약물학회
- Medici CR, "Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia", Int J Soc Psychiatry, 62, pp.12~20 (2016)
- Shargh NA, "Study of relationship between depression and quality of life in patients with chronic schizophrenia", Glob J Health Sci, 8, pp.224~229 (2016)
- Kaneda Y, "The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia", Clin Neuropharmacol, 26, pp.182~184 (2003)
- Kinon BJ, "Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials", Psychoneuroendocrinology, 28, pp.69~82 (2003)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders(DSM-5®)" (2013), American Psychiatric Pub
- Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
- Kay SR, "The positive and negative syndrome scale(PANSS) for schizophrenia", Schizophrenia bull, 13, pp.261~276 (1987)
- Addington D, "Reliability and validity of a depression rating scale for schizophrenics", Schizophr Res, 6, pp.201~208 (1992)
- 김용구, "한국어판 정신분열병의 캘거리 우울증 척도의 신뢰도 및 타당도 연구", 신경정신의학, 44(4), pp.446~455 (2005), 대한신경정신의학회
- The PHQ-9: validity of a brief depression severity measure, "Kroenke K", ~ (2001)
- 박승진, "한글판 우울증 선별도구(Patient Health Questionnaire-9, PHQ-9)의 신뢰도와 타당도", 대한불안의학회지, 6(2), pp.119~124 (2010), 대한불안의학회
- Rosenberg M, "The measurement of self-esteem, society and the adolescent self-image", pp.16~36 (1965)
- Jeon BJ, "Self-esteem: A test of its measurability", Yonsei Nonchong, pp.11~ (1974)
- Strauss JS, "The prediction of outcome in schizophrenia: Characteristics of outcome", Arch Gen Psychiatry, 27, pp.739~746 (1972)
- Kim CY, "Assessment tool of mental disease", pp.120~ (2001), Hana Press
- Hogan TP, "A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity", Psychol Med, 13, pp.177~183 (1983)
- 윤보현, "한국판 약물태도 척도의 심리측정적 특성", 대한정신약물학회지, 16(6), pp.480~487 (2005), 대한정신약물학회
- Wilkinson G, "Self-report quality of life measure for people with schizophrenia: the SQLS", Br J Psychiatry, 177, pp.42~46 (2000)
- 김진훈, "한국어판 정신분열병 삶의 질 척도의 개발과 PANSS와의 관련성", 신경정신의학, 45(5), pp.401~410 (2006), 대한신경정신의학회
- Naber D, "Subjective effects of neuroleptics predict compliance. prediction of neuroleptic treatment outcome in schizophrenia", pp.85~98 (1994), Springer
- Yoon JS, "The development of a Korean modification of the scale to measure subjective well-being under neuroleptic treatment (KmSWN)", J Korean Neuropsychiatr Assoc, 39, pp.987~998 (2000)
- Melkersson KI, "Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses", Br J Clin Pharmacol, 51, pp.317~324 (2001)
- Kinon BJ, "Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone", Psychoneuroendocrinology, 28, pp.55~68 (2003)
- Montgomery J, "Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment", Clin Psychiatry, 65, pp.1491~1498 (2004)
- 이가희, "항정신병약물을 복용중인 정신분열병 환자에서 고프로락틴혈증과 무월경 유병률 및 성기능 장애와 관련성", 신경정신의학, 48(6), pp.422~428 (2009), 대한신경정신의학회
- Kane JM, "Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine", J Clin Psychiatry, 68, pp.213~223 (2007)
- Barzman DH, "The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review", J Child Adolesc Psychopharmacol, 14, pp.593~600 (2004)
- Buckman M, "Psychological distress in hyperprolactinemic women. prolactin: basic and clinical correlates", pp.601~668 (1985), Liviana press
- Roy A, "Suicidal behavior in schizophrenics. depression in schizophrenics", pp.137~152 (1989), Springer
- Touraine P, "Long-term follow-up of 246 hyperprolactinemic patients", Acta Obstet Gynecol Scand, 80, pp.162~168 (2001)
- 심주철, "리스페리돈으로 유발된 무월경에 대한 아리피프라졸 부가치료", 대한정신약물학회지, 22(1), pp.34~39 (2011), 대한정신약물학회
- Bargiota S, "The effects of antipsychotics on prolactin levels and women’s menstruation", Schizophr Res Treatment, 2013, pp.1~10 (2013)
- Margariti M, "Quality of life in schizophreniad spectrum disorders: associations with insight and psychopathology", Psychiatry Res, 225, pp.695~701 (2015)
- von Hausswolff-Juhlin Y, "Schizophrenia and physical health problems", Acta Psychiatr Scand Suppl, 438, pp.15~21 (2009)
- 박성열, "일 대학병원 정신건강의학과 병동에서의 비정형 항정신병제 처방 경향 : 11년 관찰 연구", 대한조현병학회지, 19(2), pp.68~77 (2016), 대한조현병학회